Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathogenesis and therapy of cutaneous lymphomas--progress or impasse?

Reinhard Dummer1, Antonio Cozzio, Mirjana Urosevic

  • 1Department of Dermatology, University Hospital Zürich, Zürich, Switzerland. reinhard.dummer@usz.ch

Experimental Dermatology
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Swiss Practice Recommendations for Chronic Prurigo Including Prurigo Nodularis.

International journal of dermatology·2026
Same author

Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group.

The Journal of allergy and clinical immunology·2026
Same author

Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

The Lancet. Haematology·2026
Same author

[Diagnosis and management of chronic hand eczema in practice].

Praxis·2025
Same author

Updated Swiss Practice Recommendations for the Treatment of Acne.

Praxis·2025
Same author

Trichophyton Quinckeanum: Renaissance of the Mouse Favus Pathogen in Central Germany.

Mycoses·2025
Same journal

M2 Macrophage-Derived ENPP2/LPA Signalling Attenuates UVB-Induced Fibroblast Photoaging via LPAR1/3.

Experimental dermatology·2026
Same journal

Human-Relevant In Vitro Skin Models: From Regulatory-Validated Platforms to Emerging Technologies for Translational Dermatology.

Experimental dermatology·2026
Same journal

Large-Scale Cohort Study on the Genetic and Phenotypic Findings of Palmoplantar Keratodermas in the Chinese Population.

Experimental dermatology·2026
Same journal

52nd Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF).

Experimental dermatology·2026
Same journal

Adverse Event Profile of Apremilast: Pharmacovigilance Study Based on FDA Adverse Event Reporting System (FAERS).

Experimental dermatology·2026
Same journal

Clinical and Immunological Characteristics of Bullous Pemphigoid Patients With Psoriasis Comorbidity: A Retrospective Study.

Experimental dermatology·2026
See all related articles

This review explores the immune biology of rare skin cancers, focusing on CD4+ CD56+ hematodermic neoplasms and primary cutaneous lymphomas. New insights may lead to advanced, targeted treatments for these hematologic malignancies.

Area of Science:

  • Hematology
  • Immunology
  • Dermatology

Background:

  • The skin harbors unique hematopoietic neoplasms, primarily primary cutaneous (PC) T-cell lymphomas.
  • Understanding their immune biology is crucial for advancing treatment strategies.

Purpose of the Study:

  • To review recent advances in the immune biology of CD4+ CD56+ hematodermic neoplasms and PC T-cell and B-cell lymphomas.
  • To explore potential translation of these findings into novel therapeutic approaches.

Main Methods:

  • Review of current literature on molecular biology and immunology of cutaneous neoplasms.
  • Analysis of immune cell interactions and pathogenesis in CD4+ CD56+ hematodermic neoplasms and PC lymphomas.

Main Results:

Related Experiment Videos

  • Highlighting novel findings in the immune biology of specific CD4+ CD56+ hematodermic neoplasms.
  • Summarizing recent immunological insights into PC T-cell and B-cell lymphomas.

    • Conclusions:

    • Recent immunological discoveries offer a basis for developing more sophisticated, biology-driven treatments.
    • Future therapeutic strategies for cutaneous lymphomas will likely leverage a deeper understanding of their immune microenvironment.